来源:[1] 肥胖治疗市场竞争格局进入高速增长阶段,受GLP-1激增和口服治疗扩张推动 | DataM Intelligence (https://finance.yahoo.com/news/competitive-la ...)[2] 肥胖治疗市场竞争格局进入高速增长阶段,受GLP-1激增和口服治疗扩张推动 | DataM Intelligence - PR Newswire (https://vertexaisearch.cloud.google.com/groun ...)[3] 这3只肥胖药物股票有望在今年秋季及以后飙升 | The Motley Fool (https://vertexaisearch.cloud.google.com/groun ...)